INS and cardiac hypertrophy: Thus, the glitazone class of T2DM therapeutics (e.g., rosiglitazone and pioglitazone) activates PPARγ, stimulates brite adipocyte differentiation and increases insulin sensitivity [21], but improvement in metabolic health comes with significant side effects, including fat accumulation, hemodilution, cardiac hypertrophy and bone loss.